Torrent PharmaceuticalsQ1 FY25

Torrent Pharmaceuticals Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹4,668.8P/E: 81.8Market Cap: ₹1.8L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
- India business: Expecting low teens growth going forward, with Q1 at 15%, driven by 2.5% volume, 8.5% price, and 4% new products. Chronic segment growth remains sustainable (~13%+). - Cardiac portfolio: Losar brand expected to slip to #3 next year; growth driven by 4-5 other strong cardiac brands in future growth markets. No significant new cardiac launches anticipated soon; growth from existing brands. - US business: Targeting 5-10 product approvals this year, including oncology and diversified therapies; profitability expected post-R&D over next 2-3 years as launches ramp up. - Brazil: Underlying growth rate of 12-13% (constant currency), with 3-6 product launches annually and 19 molecules pending approval. - Germany: Mid-to-high single digits growth expected, driven by winning new tenders. - Consumer health: Key brands like Shelcal growing high teens; overall consumer segment growth supported by sustained A&P spend. Overall, growth driven by portfolio derisking, new launches, market share gains, and expansion in key regions.

See what Torrent Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The company indicates that by FY’26, it expects to be net cash positive.
  • Capital allocation going forward will depend on EBITDA and cash flow generation.
  • Acquisitions remain an integral part of the growth strategy, pursued within financial frameworks aimed at creating long-term shareholder value.
  • No specific plans for raising new capital via debt or equity were disclosed during the call.

See what Torrent Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

Yes
- The company continues to pursue acquisitions as an integral part of its growth strategy, focusing on creating long-term shareholder value. - Acquisition formats include business transfers through slump sales and company acquisitions (e.g., Curatio was a recent company acquisition). - All combinations for acquisitions are open, with a preference for acquiring 100% stakes. - Interest lies in both branded assets and good generic assets. - Focus is on existing markets like Brazil, Mexico, and potentially new markets. - No specific inorganic investment figures or timelines were provided. - R&D spend is steady at around 5% of revenues, with no material change expected for the full year. - Capital allocation is expected to be tied to cash flow and EBITDA generation, with FY'26 anticipated to be net cash positive. (Source: Pages 5, 6, 7, 8, 12, and 13)

Track Torrent Pharmaceuticals — get its next earnings analysis in your feed

How does Torrent Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisTorrent Pharmaceuticals
Rev 3Mar 3

How does Torrent Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare Torrent Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →